NCT00090259

Study to Evaluate Potential Decrease in Hospitalization Events, Time Between Events, and Increasing Longevity in Patients With Symptomatic Heart Failure (0954-948)

A Multi-center, Double-Blind, Randomized, Parallel Group Study to Evaluate the Effects of Two Different Doses of Losartan on Morbidity and Mortality in Patients With Symptomatic Heart Failure Intolerant of ACE Inhibitor Treatment

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 3,834 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter study to evaluate potential decrease in hospitalization events and time between events and increasing longevity in patients with symptomatic congestive heart failure and intolerant of first-line medication for heart failure. This study will evaluate if higher doses of the investigational drug given daily will be superior to the lower dose of the same investigational drug given daily.

Conditions

• Heart Failure

Interventions

Type	Name	Description
DRUG	Losartan 50 mg	50-mg losartan oral tablet
DRUG	Losartan 150 mg	100-mg losartan oral tablet + 50-mg losartan oral tablet

Timeline

• Start date: 2001-12-19
• Primary completion: 2009-03-31
• Completion: 2009-05-13
• First posted: 2004-08-27
• Last updated: 2024-05-16
• Results posted: 2010-08-02